Calia Margherita, Rebora Paola, Gandola Davide, Norsa Lorenzo, Maino Cesare, Romanchuk Anastasiia, Sansotta Naire, Panceri Roberto, Valle Clarissa, Valsecchi Maria Grazia, Biondi Andrea, Ippolito Davide, Zuin Giovanna
Department of Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Bicocca Bioinformatics Biostatistics and Bioimaging B4 Center, School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy; Biostatistics and Clinical Epidemiology, Fondazione IRCCS San Gerardo dei Tintori, Italy.
Clin Nutr ESPEN. 2025 Apr 30;68:14-21. doi: 10.1016/j.clnesp.2025.04.027.
Sarcopenia has a negative impact on clinical outcome in adult patients with Crohn's Disease (CD), but data on children are scarce. The aim of this study is to evaluate the prevalence of sarcopenia in children with CD using magnetic resonance enterography (MRE) and describe its relationship with baseline values and clinical outcome.
We included children with a new diagnosis of CD from 2 tertiary referral pediatric Inflammatory Bowel Disease (IBD) centres, who underwent MRE at diagnosis between 2013 and 2023. Muscle mass was assessed by measuring the total area of the total psoas muscle (tPMA) at the level of the fourth and fifth lumbar vertebrae (L4/L5). Data were compared with pediatric reference values of tPMA, and sarcopenia was defined as a tPMA below the 3rd percentile. Demographic and anthropometric data, laboratory results, clinical disease activity and endoscopic index were collected at diagnosis and during follow-up. Clinical outcomes included relapse frequency, treatment changes, surgery, and IBD-related complications.
A total of 74 children (25 females, mean age 13.2 years) with CD were enrolled in the study. Sarcopenia was present in 34/74 patients (46 %) at diagnosis. Patients with sarcopenia had a lower Body Mass Index z-score and hemoglobin levels. Clinical disease activity (assessed using the Pediatric CD Activity Index) and endoscopic activity (assessed using the Simple Endoscopic Score for CD) were significantly higher in sarcopenic compared to non-sarcopenic children (median and quartiles scores: 25 [20, 40] vs. 21 [13, 35] and 10 [5, 13] vs. 6 [3, 13], respectively). During the follow-up period (median: 35 months; range: 1-99 months), no significant differences were observed between the sarcopenic and non-sarcopenic groups in terms of the composite outcome (defined as the occurrence of at least one unfavorable event). However, the rate of flares (number per person-year) was also higher in sarcopenic children compared to non-sarcopenic ones (27 % vs. 15 %; p = 0.0679).
Sarcopenia is highly prevalent among children with CD at diagnosis. MRE-based muscle mass measurement correlates with traditional anthropometric measurements and can be valuable for comprehensive nutritional screening in pediatric CD patients. Patients with sarcopenia presented with more severe clinical, laboratory, and endoscopic findings at diagnosis; although sarcopenic children experienced more clinical relapses we were not able to show a significant association between sarcopenia and outcomes. Larger series need to be studied.
肌肉减少症对成年克罗恩病(CD)患者的临床结局有负面影响,但关于儿童的数据较少。本研究旨在利用磁共振小肠造影(MRE)评估CD患儿肌肉减少症的患病率,并描述其与基线值及临床结局的关系。
我们纳入了来自2个三级转诊儿科炎症性肠病(IBD)中心新诊断为CD的儿童,这些儿童在2013年至2023年诊断时接受了MRE检查。通过测量第四和第五腰椎(L4/L5)水平的腰大肌总面积(tPMA)来评估肌肉量。将数据与tPMA的儿科参考值进行比较,肌肉减少症定义为tPMA低于第3百分位数。在诊断时及随访期间收集人口统计学和人体测量数据、实验室结果、临床疾病活动度及内镜指数。临床结局包括复发频率、治疗变化、手术及IBD相关并发症。
本研究共纳入74例CD患儿(25例女性,平均年龄13.2岁)。诊断时34/74例患者(46%)存在肌肉减少症。肌肉减少症患者的体重指数z评分和血红蛋白水平较低。与非肌肉减少症患儿相比,肌肉减少症患儿的临床疾病活动度(采用儿科CD活动指数评估)和内镜活动度(采用CD简单内镜评分评估)显著更高(中位数及四分位数评分分别为:25[20,40]对21[13,35];10[5,13]对6[3,13])。在随访期(中位数:35个月;范围:1 - 99个月),肌肉减少症组与非肌肉减少症组在综合结局(定义为至少发生1次不良事件)方面未观察到显著差异。然而,肌肉减少症患儿的发作率(每人年发作次数)也高于非肌肉减少症患儿(27%对15%;p = 0.0679)。
CD患儿诊断时肌肉减少症的患病率很高。基于MRE的肌肉量测量与传统人体测量指标相关,对儿科CD患者的全面营养筛查有价值。肌肉减少症患者在诊断时表现出更严重的临床、实验室及内镜检查结果;尽管肌肉减少症患儿临床复发更多,但我们未能显示肌肉减少症与结局之间存在显著关联。需要研究更大规模的队列。